Tibolone

Overview

Tibolone, sold under the brand name Livial among others, is a medication which is used in menopausal hormone therapy and in the treatment of postmenopausal osteoporosis and endometriosis. The medication is available alone and is not formulated or used in combination with other medications. It is taken by mouth.[1–5] WP

Side effects of tibolone include acne and increased hair growth among others. Tibolone is a synthetic steroid with weak estrogenic, progestogenic, and androgenic activity, and hence is an agonist of the estrogen, progesterone, and androgen receptors. It is a prodrug of several metabolites. The estrogenic effects of tibolone may show tissue selectivity in their distribution.[1][6–11] WP

Tibolone was developed in the 1960s and was introduced for medical use in 1988. It is marketed widely throughout the world. The medication is not available in the United States.[5][12][13][14] WP

Uses, dosage and effects

Medical uses

Tibolone is used in the treatment of menopausal symptoms like hot flashes and vaginal atrophy, postmenopausal osteoporosis, and endometriosis. It has similar or greater effectiveness compared to older menopausal hormone therapy medications, but shares a similar side effect profile. It has also been investigated as a possible treatment for female sexual dysfunction.[1][4][15–19] WP

Tibolone reduces hot flashes, prevents bone loss, improves vaginal atrophy and urogenital symptoms (e.g., vaginal dryness, dyspareunia), and has positive effects on mood and sexual function. The medication may have greater benefits on libido than standard menopausal hormone therapy, which may be related to its androgenic effects. It is associated with low rates of vaginal bleeding and breast pain.[17][20][21] WP

A 2015 network meta-analysis of randomized controlled trials found that tibolone was associated with a significantly decreased risk of breast cancer (RR (relative risk) = 0.317). The decrease in risk was greater than that observed with most of the aromatase inhibitors and selective estrogen receptor modulators that were included in the analysis. However, paradoxically, other research has found evidence supporting an increased risk of breast cancer with tibolone.[22][23][24] WP

Available forms

Tibolone is available in the form of 2.5 mg oral tablets. It is typically used once daily at a dosage of 1.25 or 2.5 mg.[25] WP

Risks and side effects

Side effects

A report in September 2009 from Health and Human Services' Agency for Healthcare Research and Quality suggests that tamoxifen, raloxifene, and tibolone used to reduce the risk of breast cancer significantly reduce the occurrence of invasive breast cancer in midlife and older women, but also increase the risk of adverse effects.[26] WP

Tibolone can infrequently produce androgenic side effects such as acne and increased facial hair growth. Such side effects have been found to occur in 3 to 6% of treated women.[6] WP

A 2016 Cochrane review has been published on the short-term and long-term effects of tibolone, including adverse effects. Possible adverse effects of tibolone include unscheduled vaginal bleeding (OR (Odds ratio) = 2.79; incidence 13–26% more than placebo), an increased risk of breast cancer in women with a history of breast cancer (OR (Odds ratio) = 1.5) although apparently not without a history of breast cancer (OR (Odds ratio) = 0.52), an increased risk of cerebrovascular events (strokes) (OR (Odds ratio) = 1.74) and cardiovascular events (OR (Odds ratio) = 1.38), and an increased risk of endometrial cancer (OR (Odds ratio) = 2.04). However, most of these figures are based on very low-quality evidence.[27] WP

Tibolone has been associated with increased risk of endometrial cancer in most studies.[28] WP

Pharmacology

Pharmacodynamics

Tibolone possesses a complex pharmacology and has weak estrogenic, progestogenic, and androgenic activity. Tibolone, 3α-hydroxytibolone, and 3β-hydroxytibolone act as agonists of the estrogen receptors. Tibolone and its metabolite δ⁴-tibolone act as agonists of the progesterone and androgen receptors, while 3α-hydroxytibolone and 3β-hydroxytibolone, conversely, act as antagonists of these receptors. Relative to other progestins, tibolone, including its metabolites, has been described as possessing moderate functional antiestrogenic activity (that is, progestogenic activity), moderate estrogenic activity, high androgenic activity, and no clinically significant glucocorticoid, antiglucocorticoid, mineralocorticoid, or antimineralocorticoid activity. The ovulation-inhibiting dosage of tibolone is 2.5 mg/day.[1][6][8][29][30] WP

Estrogenic activity

Tibolone and its two major active metabolites, 3α-hydroxytibolone and 3β-hydroxytibolone, act as potent, fully activating agonists of the estrogen receptor (ER), with a high preference for the ERα. These estrogenic metabolites of tibolone have much weaker activity as estrogens than estradiol (e.g., have 3–29% of the affinity of estradiol for the ER (estrogen receptor)), but occur at relatively high concentrations that are sufficient for full and marked estrogenic responses to occur.[1][8][10][29][31] WP

The estrogenic effects of tibolone show tissue selectivity in their distribution, with desirable effects in bone, the brain, and the vagina, and lack of undesirable action in the uterus, breast, and liver. The observations of tissue selectivity with tibolone have been theorized to be the result of metabolism, enzyme modulation (e.g., of estrogen sulfatase and estrogen sulfotransferase), and receptor modulation that vary in different target tissues. This selectivity differs mechanistically from that of selective estrogen receptor modulators (SERMs) such as tamoxifen, which produce their tissue selectivity via means of modulation of the ER. As such, to distinguish it from SERMs, tibolone has been variously described as a "selective tissue estrogenic activity regulator" (STEAR), "selective estrogen enzyme modulator" (SEEM), or "tissue-specific receptor and intracrine mediator" (TRIM). More encompassingly, tibolone has also been described as a "selective progestogen, estrogen, and androgen regulator" (SPEAR), which is meant to reflect the fact that it is tissue-selective and that it regulates effects not only of estrogens but of all three of the major sex hormone classes. Although indications of tissue selectivity with tibolone have been observed, the medication has paradoxically nonetheless been associated with increased risk of endometrial cancer and breast cancer in clinical studies.[7][9][10][11][27][29][30] WP

It was reported in 2002 that tibolone or its metabolite δ⁴-tibolone is transformed by aromatase into the potent estrogen 7α-methylethinylestradiol in women, analogously to the transformation of norethisterone into ethinylestradiol. Controversy and disagreement followed when other researchers contested the findings however. By 2008, these researchers had asserted that tibolone is not aromatized in women and that the previous findings of 7α-methylethinylestradiol detection were merely a methodological artifact. In accordance, a 2009 study found that an aromatase inhibitor had no effect on the estrogenic potencies of tibolone or its metabolites in vitro, unlike the case of testosterone. In addition, another 2009 study found that the estrogenic effects of tibolone on adiposity in rats do not require aromatization (as indicated by the use of aromatase knockout mice), further in support that 3α-hydroxytibolone and 3β-hydroxytibolone are indeed responsible for such effects. These findings are also in accordance with the fact that tibolone decreases sex hormone-binding globulin (SHBG) levels by 50% in women and does not increase the risk of venous thromboembolism (VTE) (RR (Rate ratio) = 0.92), which would not be expected if the medication formed a potent, liver metabolism-resistant estrogen similar to ethinylestradiol in important quantities. (For comparison, combined oral contraceptives containing ethinylestradiol, due mostly or completely to the estrogen component, have been found to increase SHBG levels by 200 to 400% and to increase the risk of VTE by about 4-fold (OR (odds ratio) = 4.03).)[1][8][32–42] WP

In spite of the preceding, others have held, as recently as 2011, that tibolone is converted into 7α-methylethinylestradiol in small quantities. They have claimed that 19-nortestosterone derivatives like tibolone, due to lacking a C19 methyl group, indeed are not substrates of the classical aromatase enzyme, but instead are still transformed into the corresponding estrogens by other cytochrome P450 monooxygenases. In accordance, the closely structurally related AAS trestolone (7α-methyl-19-nortestosterone or 17α-desethynyl-δ⁴-tibolone) has been found to be transformed into 7α-methylestradiol by human placental microsomes in vitro. Also in accordance, considerably disproportionate formation of ethinylestradiol occurs when norethisterone is taken orally (and hence undergoes first-pass metabolism in the liver) relative to parenterally, despite the absence of aromatase in the adult human liver.[36][38][43–48] WP

Progestogenic activity

Tibolone and δ⁴-tibolone act as agonists of the progesterone receptor (PR). Tibolone has low affinity of 6% of that of promegestone for the PR, while δ⁴-tibolone has high affinity of 90% of that of promegestone for the PR. In spite of its high affinity for the PR however, δ⁴-tibolone possesses only weak progestogenic activity, about 13% of that of norethisterone. The weak progestogenic activity of tibolone may not be sufficient to fully counteract estrogenic activity of tibolone in the uterus and may be responsible for the increased risk of endometrial cancer that has been observed with tibolone in women in large cohort studies.[1][44][49] WP

Androgenic activity

Tibolone, mainly via δ⁴-tibolone, has androgenic activity. Whereas tibolone itself has only about 6% of the affinity of metribolone for the androgen receptor, δ⁴-tibolone has relatively high affinity of about 35% of the affinity of metribolone for this receptor. At typical clinical dosages in women, the androgenic effects of tibolone are weak. However, relative to other 19-nortestosterone progestins, the androgenic activity of tibolone is high, with a potency comparable to that of testosterone. Indeed, the androgenic effects of tibolone have been ranked as stronger than those of all other commonly used 19-nortestosterone progestins (e.g., norethisterone, levonorgestrel, others).[1][44] WP

The androgenic effects of tibolone have been postulated to be involved in the reduced breast cell proliferation, reduced breast cancer risk, improvement in sexual function, less unfavorable changes in hemostatic parameters relative to estrogen–progestogen combinations, and changes in liver protein synthesis (e.g., 30% reductions in HDL cholesterol levels, 20% reduction in triglyceride levels, and 50% reduction in SHBG levels) observed with tibolone. They are also responsible for the androgenic side effects of tibolone such as acne and increased hair growth in some women.[1][6][44] WP

Other activities

Tibolone, 3α-hydroxytibolone, and 3β-hydroxytibolone act as antagonists of the glucocorticoid and mineralocorticoid receptors, with preference for the mineralocorticoid receptor. However, their affinities for these receptors are low, and tibolone has been described as possessing no clinically significant glucocorticoid, antiglucocorticoid, mineralocorticoid, or antimineralocorticoid activity.[1][8][30] WP

Pharmacokinetics

The mean oral bioavailability of tibolone is 92%. Its plasma protein binding is 96.3%. It is bound to albumin, and both tibolone and its metabolites have low affinity for SHBG. Tibolone is metabolized in the liver and intestines. It is a prodrug and is rapidly transformed into several metabolites, including δ⁴-tibolone, 3α-hydroxytibolone, and 3β-hydroxytibolone, as well as sulfate conjugates of these metabolites. 3α-Hydroxytibolone is formed by 3α-hydroxysteroid dehydrogenase, 3β-hydroxytibolone is formed by 3β-hydroxysteroid dehydrogenase, δ⁴-tibolone is formed by Δ⁵⁻⁴-isomerase, and the sulfate conjugates of tibolone and its metabolites are formed by sulfotransferases, mainly SULT2A1. The sulfate conjugates can be transformed back into free steroids by steroid sulfatase. Following a single oral dose of 2.5 mg tibolone, peak serum levels of tibolone were 1.6 ng/mL, of δ⁴-tibolone were 0.8 ng/mL, of 3α-hydroxytibolone were 16.7 ng/mL, and of 3β-hydroxytibolone were 3.7 ng/mL after 1 to 2 hours. The elimination half-life of tibolone is 45 hours. It is excreted in urine 40% and feces 60%.[1][6][30][49–53] WP

History

History

Tibolone was developed in the 1960s. It was first introduced in the Netherlands in 1988, and was subsequently introduced in the United Kingdom in 1991.[12][13][54] WP

Legal status

Generic names

Tibolone is the generic name of the drug and its INN (International Nonproprietary Name), USAN (United States Adopted Name), BAN (British Approved Name), DCF (Dénomination Commune Française), and JAN (Japanese Accepted Name). It is also known by its developmental code name ORG-OD-14.[2][3][6] WP

Brand names

Tibolone is marketed under the brand names Livial, Tibofem, and Ladybon among others.[2][3][5] WP

Availability

Tibolone is used widely in the European Union, Asia, Australasia, and elsewhere in the world, but is not available in the United States.[5][14][55] WP

Legal status

Tibolone is a Schedule IV controlled substance in Canada under the 1996 Controlled Drugs and Substances Act. It is classified as an anabolic steroid under this act, due to its relatively high activity as an AR (androgen receptor) agonist, and is the only norethisterone (17α-ethynyl-19-nortestosterone) derivative that is classified as such. Tibolone is banned by WADA (World Anti-Doping Agency) as an anabolic steroid category S1 largely due to its conversion to the Isotibolone metabolite, which is a potent androgen.[56][57][58] WP

Chemistry

Formula

C21H28O2 PC

CAS number

5630-53-5 PC

Molar mass (g/mol)

312.4 PC

IUPAC name (computed by PubChem)

(7R,8R,9S,13S,14S,17R)-17-ethynyl-17-hydroxy-7,13-dimethyl-1,2,4,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one PC

SMILES

C[C@@H]1CC2=C(CCC(=O)C2)[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C#C)O PC

InChIKey

WZDGZWOAQTVYBX-XOINTXKNSA-N PC

PubChem CID

444008

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. August 2005. doi:10.1080/13697130500148875 · PMID 16112947
2. Other Ganellin CR, Triggle DJ. Dictionary of Pharmacological Agents. 21 November 1996
3. Other Morton IK, Hall JM. Concise Dictionary of Pharmacological Agents: Properties and Synonyms. 6 December 2012
4. Journal / agency Tibolone
5. Other Tibolone International
6. Journal / agency Albertazzi P, Di Micco R, Zanardi E. Tibolone: a review. Maturitas. November 1998. doi:10.1016/S0378-5122(98)00059-0 · PMID 9881330
7. Other Cano A. Menopause: A Comprehensive Approach. 2 November 2017
8. Journal / agency Escande A, Servant N, Rabenoelina F, Auzou G, Kloosterboer H, Cavaillès V, Balaguer P, Maudelonde T. Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites. The Journal of Steroid Biochemistry and Molecular Biology. August 2009. doi:10.1016/j.jsbmb.2009.03.008 · PMID 19464167
9. Other Falcone T, Hurd WW. Clinical Reproductive Medicine and Surgery: A Practical Guide. 14 June 2017
10. Other Schneider HP, Naftolin F. Climacteric Medicine - Where Do We Go?: Proceedings of the 4th Workshop of the International Menopause Society. 22 September 2004
11. Other King T, Brucker MC. Pharmacology for Women's Health. 25 October 2010
12. Other Fritz MA, Speroff L. Clinical Gynecologic Endocrinology and Infertility. 28 March 2012
13. Journal / agency de Vries CS, Bromley SE, Thomas H, Farmer RD. Tibolone and endometrial cancer: a cohort and nested case-control study in the UK. Drug Safety. 2005. doi:10.2165/00002018-200528030-00005 · PMID 15733028
14. Other Segal SJ, Mastroianni L. Hormone Use in Menopause and Male Andropause: A Choice for Women and Men: A Choice for Women and Men. 4 October 2003
15. Journal / agency Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A. Hormone therapy for endometriosis and surgical menopause. The Cochrane Database of Systematic Reviews. January 2009. doi:10.1002/14651858.CD005997.pub2 · PMID 19160262 · PMC13138584
16. Journal / agency Lazovic G, Radivojevic U, Marinkovic J. Tibolone: the way to beat many a postmenopausal ailments. Expert Opinion on Pharmacotherapy. April 2008. doi:10.1517/14656566.9.6.1039 · PMID 18377345
17. Journal / agency Garefalakis M, Hickey M. Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence. Clinical Interventions in Aging. 2008. doi:10.2147/CIA.S1043 · PMID 18488873 · PMC2544356
18. Journal / agency Vavilis D, Zafrakas M, Goulis DG, Pantazis K, Agorastos T, Bontis JN. Hormone therapy for postmenopausal breast cancer survivors: a survey among obstetrician-gynaecologists. European Journal of Gynaecological Oncology. 2009. PMID 19317264
19. Journal / agency Ziaei S, Moghasemi M, Faghihzadeh S. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women. Climacteric. April 2010. doi:10.1080/13697130903009195 · PMID 19731119
20. Journal / agency Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas. May 2005. doi:10.1016/j.maturitas.2005.02.011 · PMID 15883105
21. Journal / agency Davis SR. The effects of tibolone on mood and libido. Menopause. 2002. doi:10.1097/00042192-200205000-00004 · PMID 11973439
22. Journal / agency Mocellin S, Pilati P, Briarava M, Nitti D. Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials. Journal of the National Cancer Institute. February 2016. doi:10.1093/jnci/djv318 · PMID 26582062
23. Journal / agency Erel CT, Senturk LM, Kaleli S. Tibolone and breast cancer. Postgraduate Medical Journal. October 2006. doi:10.1136/pgmj.2005.037184 · PMID 17068276 · PMC2653908
24. Journal / agency Wang PH, Cheng MH, Chao HT, Chao KC. Effects of tibolone on the breast of postmenopausal women. Taiwanese Journal of Obstetrics & Gynecology. June 2007. doi:10.1016/S1028-4559(07)60005-9 · PMID 17638619
25. Other Meeta. Postmenopausal Osteoporosis: Basic and Clinical Concepts. 15 December 2013
26. Other Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects, New Report Says. September 2009
27. Journal / agency Formoso G, Perrone E, Maltoni S, Balduzzi S, Wilkinson J, Basevi V, Marata AM, Magrini N, D'Amico R, Bassi C, Maestri E. Short-term and long-term effects of tibolone in postmenopausal women. The Cochrane Database of Systematic Reviews. October 2016. doi:10.1002/14651858.CD008536.pub3 · PMID 27733017 · PMC6458045
28. Journal / agency Sjögren LL, Mørch LS, Løkkegaard E. Hormone replacement therapy and the risk of endometrial cancer: A systematic review. Maturitas. September 2016. doi:10.1016/j.maturitas.2016.05.013 · PMID 27451318
29. Other Falcone T, Hurd WW. Clinical Reproductive Medicine and Surgery: A Practical Guide. 22 May 2013
30. Journal / agency Purdie DW. What is tibolone--and is it a SPEAR?. Climacteric. September 2002. doi:10.1080/cmt.5.3.236.239 · PMID 12419081
31. Journal / agency Schoonen WG, Deckers GH, de Gooijer ME, de Ries R, Kloosterboer HJ. Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives. The Journal of Steroid Biochemistry and Molecular Biology. November 2000. doi:10.1016/s0960-0760(00)00125-4 · PMID 11162927
32. Journal / agency Wiegratz I, Sänger N, Kuhl H. Formation of 7 alpha-methyl-ethinyl estradiol during treatment with tibolone. Menopause. 2002. doi:10.1097/00042192-200207000-00011 · PMID 12082366
33. Journal / agency de Gooyer ME, Oppers-Tiemissen HM, Leysen D, Verheul HA, Kloosterboer HJ. Tibolone is not converted by human aromatase to 7alpha-methyl-17alpha-ethynylestradiol (7alpha-MEE): analyses with sensitive bioassays for estrogens and androgens and with LC-MSMS. Steroids. March 2003. doi:10.1016/S0039-128X(02)00184-8 · PMID 12628686
34. Journal / agency Raobaikady B, Parsons MF, Reed MJ, Purohit A. Lack of aromatisation of the 3-keto-4-ene metabolite of tibolone to an estrogenic derivative. Steroids. July 2006. doi:10.1016/j.steroids.2006.03.006 · PMID 16712888
35. Journal / agency Zacharia LC, Jackson EK, Kloosterboer HJ, Imthurn B, Dubey RK. Conversion of tibolone to 7alpha-methyl-ethinyl estradiol using gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry: interpretation and clinical implications. Menopause. 2006. doi:10.1097/01.gme.0000227331.49081.d7 · PMID 17006378
36. Journal / agency Kuhl H, Wiegratz I. Can 19-nortestosterone derivatives be aromatized in the liver of adult humans? Are there clinical implications?. Climacteric. August 2007. doi:10.1080/13697130701380434 · PMID 17653961
37. Journal / agency Dröge MJ, Oostebring F, Oosting E, Verheul HA, Kloosterboer HJ. 7alpha-Methyl-ethinyl estradiol is not a metabolite of tibolone but a chemical stress artifact. Menopause. 2007. doi:10.1097/01.gme.0000247015.63877.d4 · PMID 17237734
38. Journal / agency Kloosterboer HJ. Tibolone is not aromatized in postmenopausal women. Climacteric. April 2008. doi:10.1080/13697130701752087 · PMID 18365860
39. Journal / agency Van Sinderen ML, Boon WC, Ederveen AG, Kloosterboer HJ, Simpson ER, Jones ME. The estrogenic component of tibolone reduces adiposity in female aromatase knockout mice. Menopause. 2009. doi:10.1097/gme.0b013e31818fb20b · PMID 19182696
40. Journal / agency Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. Journal of Thrombosis and Haemostasis. May 2010. doi:10.1111/j.1538-7836.2010.03839.x · PMID 20230416
41. Other IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; World Health Organization; International Agency for Research on Cancer. Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. 2007
42. Journal / agency Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. Journal of Thrombosis and Thrombolysis. January 2016. doi:10.1007/s11239-015-1311-6 · PMID 26780736 · PMC4715842
43. Journal / agency Kuhl H, Wiegratz I. In vivo conversion of TIB to MEE not an artifact generated by heat. Menopause. 2007. doi:10.1097/01.gme.0000264447.18842.da · PMID 17496790
44. Journal / agency Kuhl H. Pharmacology of progestogens. Journal für Reproduktionsmedizin und Endokrinologie. 2011
45. Journal / agency LaMorte A, Kumar N, Bardin CW, Sundaram K. Aromatization of 7 alpha-methyl-19-nortestosterone by human placental microsomes in vitro. The Journal of Steroid Biochemistry and Molecular Biology. February 1994. doi:10.1016/0960-0760(94)90160-0 · PMID 8142308
46. Journal / agency Kuhnz W, Heuner A, Hümpel M, Seifert W, Michaelis K. In vivo conversion of norethisterone and norethisterone acetate to ethinyl etradiol in postmenopausal women. Contraception. December 1997. doi:10.1016/S0010-7824(97)00174-1 · PMID 9494772
47. Journal / agency Friedrich C, Berse M, Klein S, Rohde B, Höchel J. In Vivo Formation of Ethinylestradiol After Intramuscular Administration of Norethisterone Enantate. Journal of Clinical Pharmacology. June 2018. doi:10.1002/jcph.1079 · PMID 29522253
48. Journal / agency Hata S, Miki Y, Saito R, Ishida K, Watanabe M, Sasano H. Aromatase in human liver and its diseases. Cancer Medicine. June 2013. doi:10.1002/cam4.85 · PMID 23930207 · PMC3699842
49. Journal / agency Verhoeven CH, Vos RM, Delbressine LP. The in vivo metabolism of tibolone in animal species. European Journal of Drug Metabolism and Pharmacokinetics. 2002. doi:10.1007/BF03190399 · PMID 11996321
50. Other Tibolone 2.5 mg Tablets
51. Journal / agency Falany JL, Macrina N, Falany CN. Sulfation of tibolone and tibolone metabolites by expressed human cytosolic sulfotransferases. The Journal of Steroid Biochemistry and Molecular Biology. April 2004. doi:10.1016/j.jsbmb.2004.01.005 · PMID 15145448
52. Journal / agency Wang M, Ebmeier CC, Olin JR, Anderson RJ. Sulfation of tibolone metabolites by human postmenopausal liver and small intestinal sulfotransferases (SULTs). Steroids. May 2006. doi:10.1016/j.steroids.2005.11.003 · PMID 16360722
53. Journal / agency Falany JL, Falany CN. Interactions of the human cytosolic sulfotransferases and steroid sulfatase in the metabolism of tibolone and raloxifene. The Journal of Steroid Biochemistry and Molecular Biology. 2007. doi:10.1016/j.jsbmb.2007.03.046 · PMID 17662596 · PMC2697607
54. Journal / agency Berning B, Bennink HJ, Fauser BC. Tibolone and its effects on bone: a review. Climacteric. June 2001. doi:10.1080/cmt.4.2.120.136 · PMID 11428176
55. Other Goldstein I, Meston CM, Davis S, Traish A. Women's Sexual Function and Dysfunction: Study, Diagnosis and Treatment. 17 November 2005
56. Other Controlled Drugs and Substances Act (S.C. 1996, c. 19). 2016-11-30
57. Other Controlled Drugs and Substances Act SCHEDULE IV (Sections 2, 4 to 7.1, 10, 29, 55 and 60). 2020-10-29
58. Other 2022 Prohibited List: SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.